🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Relapsed Hematologic Malignancy

A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003 NCT07623798Phase 31 site📍 Shanghai Innovent Biologics (Suzhou) Co. Ltd. · Tests: Pomalidomide Capsules, Bortezomib for Injection, Daratumumab Injection (Subcutaneous Injection), IBI3003, Selinexor Tab… A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) NCT05519085Phase 3266 sites📍 Los Alamitos📍 San Diego📍 West Hollywood Celgene · Tests: mezigdomide, Pomalidomide, Bortezomib, Dexamethasone Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma NCT05530421Phase 23 sites📍 Coral Gables📍 Deerfield Beach📍 Miami University of Miami · Tests: Selinexor, Venetoclax, Dexamethasone Evaluation of Treatment Efficacy According to Risk Group in Relapsed Childhood Acute Lymphoblastic Leukemia NCT05827549Phase 210 sites📍 Daegu📍 Daejeon📍 Hwasun Ho Joon Im · Tests: Reinduction(4weeks), Cosolodation 1st(3weeks), Consolidation 2nd(3weeks), Blinatumomab 1st(High Risk Group)_4 Weeks, Bl… CD7 CAR-T Bridging to alloHSCT for R/R CD7+Malignant Hematologic Diseases NCT05827835Phase 1, Phase 21 site📍 Hangzhou Zhejiang University · Tests: CD7 CAR-T cells injection, Allogeneic hematopoietic stem cell transplantation Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention NCT06686108Phase 21 site📍 Shanghai Shanghai General Hospital, Shanghai Jiao Tong University Sc… · Tests: Azacitidine (AZA) Days 1 - 5, Decitabine (DAC), Venetoclax Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia NCT05506332Phase 12 sites📍 Edegem📍 Roeselare University Hospital, Antwerp · Tests: Venetoclax, 6-mercaptopurine CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies NCT07106749Phase 11 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: CD180 CART Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies NCT07284433Phase 1, Phase 213 sites📍 Chicago📍 Evanston📍 Providence AvenCell Therapeutics, Inc. · Tests: Cyclophosphamide (Non-IMP, Lymphodepletion), Fludarabine (Non-IMP, Lymphodepletion), Allo-QuadCAR01-T Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse NCT06928662Phase 1, Phase 21 site📍 Seattle Fred Hutchinson Cancer Center · Tests: Decitabine, Bone Marrow Aspiration, Bone Marrow Biopsy, Chest Radiography, Cytarabine Donor Derived CD117 CAR-T Cells in the Treatment of R/R Acute Myeloid Leukemia NCT07144020EARLY Phase 11 site📍 Hangzhou Zhejiang University · Tests: CD117 CAR T-cells CAV Regimen for R/R Ph- B-ALL NCT05657652NA1 site📍 Suzhou The First Affiliated Hospital of Soochow University · Tests: cladribine, cytarabine,venetoclax A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies NCT05908409Phase 1, Phase 211 sites📍 Santander📍 Salamanca📍 Barcelona IDP Discovery Pharma S.L. · Tests: IDP-121 SynKIR-310 for Relapsed/Refractory B-NHL NCT06544265Phase 15 sites📍 Denver📍 Atlanta📍 Fairway Verismo Therapeutics · Tests: SynKIR-310 A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor NCT06615193Phase 18 sites📍 Zhengzhou📍 Suzhou📍 Suzhou Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Tests: HDM2005 A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM) NCT07227311Phase 259 sites📍 Los Alamitos📍 Torrance📍 Whittier GlaxoSmithKline · Tests: Belantamab mafodotin, Dexamethasone, Pomalidomide, Bortezomib, Carfilzomib CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma NCT05054257Phase 11 site📍 Prague Institute of Hematology and Blood Transfusion, Czech Republ… · Tests: Autologous CAR19 T lymphocytes VHAG in Treating R/R T-ALL/LBL NCT06742463Phase 21 site📍 Hangzhou First Affiliated Hospital of Zhejiang University · Tests: Venetoclax, homoharringtonine, Cytarabine (Ara-C), G-CSF Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL NCT06874946Phase 1, Phase 21 site📍 Beijing Peking University People's Hospital · Tests: CD5-targeted CAR-T cells Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia NCT03136146Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Bortezomib, Clofarabine, Cyclophosphamide, Dexamethasone, Etoposide CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia NCT07328503Phase 21 site📍 Bethesda National Cancer Institute (NCI) · Tests: CD22 CAR-transduced T cells, Cyclophosphamide, Fludarabine A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma NCT04973605Phase 1, Phase 274 sites📍 Birmingham📍 Duarte📍 Irvine BeOne Medicines · Tests: Sonrotoclax, Dexamethasone, Carfilzomib, Daratumumab, Pomalidomide An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies NCT07101705EARLY Phase 11 site📍 Wuhan Union Hospital, Tongji Medical College, Huazhong University… · Tests: OriV508 Injection Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies NCT06316427Phase 1, Phase 24 sites📍 Beijing📍 Shanghai📍 Shanghai Beijing GoBroad Hospital · Tests: Autologous CD7 CAR T-cell, Prior-HSCT donor-derived CD7 CAR T-cell, New donor-derived CD7 CAR T-cell Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Acute Myeloid Leukemia (AML) NCT05580601Phase 1, Phase 21 site📍 Cincinnati Children's Hospital Medical Center, Cincinnati · Tests: CIML-NK Cells A Pilot Study of Soursop Tea in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Multiple Myeloma (MM) NCT07771803EARLY Phase 11 site📍 Camden Roger Strair · Tests: Soursop tea CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia NCT03896269Phase 11 site📍 Houston M.D. Anderson Cancer Center · Tests: Liposome-encapsulated Daunorubicin-Cytarabine CD19 Chimeric Antigen Receptor (CAR) T Cells in Adults With Relapsed/Refractory CD19 Positive Acute Lymphoblastic Leukemia NCT07361029Phase 11 site📍 Riyadh King Faisal Specialist Hospital & Research Center · Tests: CAR T cells chimeric antigen receptor cells Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia NCT03263572Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Blinatumomab, Cytarabine, Methotrexate, Ponatinib A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD" NCT07382739Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Elranatamab
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy